Skip to main content
Top

18-04-2024 | Images in clinical gastroenterology

Serous cystic neoplasm of pancreas with surgical obstructive jaundice and double duct sign: Cystadenoma or cystadenocarcinoma?

Authors: Vibhu Jain, Vaneet Jearth, Pankaj Gupta, Aravind Sekar, Kailash Chand Kurdia

Published in: Indian Journal of Gastroenterology

Login to get access

Excerpt

Serous cystic neoplasm (SCN) is a cystic lesion of the pancreas, with a large number of patients being diagnosed incidentally. It is generally considered a benign entity, with limited cases of serous cystadenocarcinoma reported in literature [1]. There is no clear pathological characteristic to differentiate cystadenoma or cystadenocarcinoma even with local invasion on radiological imaging in the absence of distant metastasis [2]. A 63-year-old male presented with surgical obstructive jaundice (SOJ) and pruritis with no history of cholangitis and weight loss for one month. Blood investigations revealed conjugated hyperbilirubinemia (total and conjugated bilirubin levels of 6.4 mg/dL and 4.9 mg/dL, respectively, and a raised alkaline phosphatase of 396 IU/mL). Radiological investigations showed a large microcystic lesion in the head of the pancreas with mild attenuation in the portal vein (PV) caliber and close abutment of the superior mesenteric artery (SMA) and superior mesenteric vein (SMV) with overall features suggestive of an SCN (Fig. 1). However, findings such as a positive double duct sign and involvement of adjacent vascular structures along with the clinical presentation of SOJ were suspicious for malignancy. The patient was successfully managed with classical pancreaticoduodenectomy with sleeve resection of superior mesenteric vein and portal vein with longitudinal venorrhaphy (Fig. 2A). A replaced right hepatic artery (rRHA) was seen coursing through the tumor and had to be sacrificed owing to an inadequate stump of the gastroduodenal artery to allow reconstruction after ensuring a good pulsatile back-bleed from the distal part of the artery. The final histopathological report revealed serous cystadenoma with negative margins (Fig. 2B). SCN rarely presents with SOJ [3]. Distant metastasis is the only definitive sign of cystadenocarcinoma; radiological double duct sign along with locally aggressive features such as involvement of adjacent vascular structure does not always favor cystadenocarcinoma or exclude cystadenoma; however, surgical resection with negative margins should be the aim.
Appendix
Available only for authorised users
Literature
1.
go back to reference Strobel O, Z’graggen K, Schmitz-Winnenthal FH, et al. Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion. 2003;68:24–33.CrossRefPubMed Strobel O, Z’graggen K, Schmitz-Winnenthal FH, et al. Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion. 2003;68:24–33.CrossRefPubMed
2.
go back to reference Friebe V, Keck T, Mattern D, et al. Serous cystadenocarcinoma of the pancreas: management of a rare entity. Pancreas. 2005;31:182–7.CrossRefPubMed Friebe V, Keck T, Mattern D, et al. Serous cystadenocarcinoma of the pancreas: management of a rare entity. Pancreas. 2005;31:182–7.CrossRefPubMed
3.
go back to reference Gilmore RC, Kalmar CL, He J. Serous cystadenoma of the pancreas : rare presentation of obstructive jaundice. Am Surg. 2021;87:1845–7.CrossRefPubMed Gilmore RC, Kalmar CL, He J. Serous cystadenoma of the pancreas : rare presentation of obstructive jaundice. Am Surg. 2021;87:1845–7.CrossRefPubMed
Metadata
Title
Serous cystic neoplasm of pancreas with surgical obstructive jaundice and double duct sign: Cystadenoma or cystadenocarcinoma?
Authors
Vibhu Jain
Vaneet Jearth
Pankaj Gupta
Aravind Sekar
Kailash Chand Kurdia
Publication date
18-04-2024
Publisher
Springer India
Published in
Indian Journal of Gastroenterology
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-024-01584-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.